Penumbra Inc is a medical technology company that specializes in the development and manufacturing of innovative devices for the treatment of various vascular and neurological conditions. The company focuses on creating solutions that are minimally invasive and designed to improve patient outcomes in areas such as stroke intervention, peripheral artery disease, and other critical health challenges. Penumbra leverages advanced engineering and regulatory expertise to offer state-of-the-art products that enhance the capabilities of healthcare professionals and provide better care for patients. Read More
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of defensive posturing to a full-scale dealmaking renaissance. Driven by a record-shattering $2 trillion in "dry powder" and a
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE: PEN) for an enterprise value of approximately $14.5 billion. The deal, representing Boston Scientific’s largest acquisition in over
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
The U.S. stock market reached a historic milestone on January 27, 2026, as the S&P 500 (NYSEARCA:SPY) climbed to a fresh all-time high of 6,980.75, tantalizingly close to the psychologically significant 7,000 level. Driven by a surge in the Nasdaq Composite (NASDAQ:QQQ), which
As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States merger and acquisition (M&A) market has roared back to life with a ferocity that has caught even seasoned Wall Street analysts
As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For the first time in years, the spotlight has moved away from the tech behemoths of the "Magnificent Seven" and onto
The past six months have been a windfall for Penumbra’s shareholders. The company’s stock price has jumped 55.5%, setting a new 52-week high of $355.93 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Expensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (NYSE: MS) recently released a bullish outlook for the year, projecting a
Shares of medical device company Penumbra (NYSE:PEN)
jumped 12.1% in the afternoon session after the company agreed to be acquired by Boston Scientific in a deal valued at approximately $14.5 billion.
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
